

Cáncer de pulmón de células no pequeñas Non Small Cell Lung Carcinoma

Estudio observacional para evaluar el manejo clínico en la vida real y los resultados de participantes con CPNM avanzado positivo para LAQ tratados con alectinib

An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib

Trial Status
Activo, sin reclutar

Trial Runs In
25 Countries

Trial Identifier
NCT04764188 MO42122

La información se obtuvo directamente de sitios web de registros públicos, como ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., y no se ha editado.

Official Title:

A Multicenter Non-Interventional Cohort Study to Evaluate the Real-World Clinical Management and Outcomes of Patients Diagnosed With ALK-Positive Advanced NSCLC Treated With Alectinib (ReAlec)

Trial Summary:

This study aims to characterize the clinical management and outcomes of participants diagnosed with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who are being treated with alectinib in real-world clinical practice.

Hoffmann-La Roche
Sponsor

N/A
Phase

NCT04764188 MO42122
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
#18 Years

Healthy Volunteers
No

Inclusion Criteria:

- Confirmed diagnosis of advanced NSCLC (stage IIIB, IIIC, IVA, or IVB) on or after the date of local approval for alectinib as first-line treatment and/or second-line treatment for ALK-positive advanced NSCLC and planned to receive treatment as per routine for at least one cycle (28 days) while on study

ForPatients

by Roche

- ALK-positive as confirmed by immunohistochemistry (IHC), fluorescent in situ hybridization (FISH), next generation sequencing (NGS), or other non-specified sequencing methods, documented prior to receiving treatment with an ALK inhibitor
- Cohort 1: Currently receiving, or planned to receive, treatment for ALK-positive advanced NSCLC with alectinib as first-line treatment
- Cohort 2: Planned to receive treatment for ALK-positive advanced NSCLC with alectinib as second-line treatment
- Able to be followed-up by participating site
- Participants with advanced NSCLC who have CNS metastases are eligible for inclusion

Exclusion Criteria:

- Participants not receiving alectinib for the treatment of ALK-positive advanced NSCLC according to standard of care and in line with local product information
- Participants not receiving the Roche studied medicinal product
- Participants who have received or are currently receiving alectinib as an investigational study drug in a clinical trial for the treatment of advanced NSCLC